Neoadjuvant treatment of rectal cancer:where are we now?

作     者：Aparna Kalyan Shaina Rozelle Al Benson III 

作者机构：Developmental Therapeutics Program of Division of Hematology&OncologyRobert H.Lurie Comprehensive Cancer Center of Northwestern UniversityChicagoIL USA Division of Hematology&OncologyRobert H.Lurie Comprehensive Cancer Center of Northwestern UniversityChicagoIL USA 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2016年第4卷第3期

页      面：206-209,I0002页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER 

主　　题：rectal cancer neoadjuvant chemoradiation 5-fluorouracil local recurrence 

摘      要：Introduction Colorectal cancer is the third leading cause of cancer-related mortality in the United States[1].Of this group of patients,approximately 39000 cases of rectal cancer were reported in the US in 20151].Treatment of rectal cancer truly requires combinatorial therapy with surgery,chemotherapy and radiation(RT),which now comprise the cornerstone of treatment for rectal cancer.